Floatz logo

Nivolumab

Smoldering Multiple Myeloma

Massachusetts General Hospitalmonoclonal_antibodyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
81/ 100

Competitive context

30 Active assets in the Smoldering Multiple Myeloma cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Regeneron Pharmaceuticals
Phase 3BB
FILGRASTIM
Regeneron Pharmaceuticals
Phase 3BB
cc-5013
Irene Ghobrial, MD
Phase 3BB
Linvoseltamab
Regeneron Pharmaceuticals
Phase 3BB
DARATUMUMAB
Regeneron Pharmaceuticals
Phase 3BB

View all 48 →

Same molecule, other indications

Nivolumab is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
renal carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →